Dr. Reddy’s Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹5626
- Today's High:
- ₹5717
- Open Price:
- ₹5639.95
- 52W Low:
- ₹3965.0985
- 52W High:
- ₹5986.2002
- Prev. Close:
- ₹5613.8
- Volume:
- 516202
Company Statistics
- Market Cap.:
- ₹937.09 billion
- Book Value:
- 1475.604
- Revenue TTM:
- ₹261.11 billion
- Operating Margin TTM:
- 23.57%
- Gross Profit TTM:
- ₹94.01 billion
- Profit Margin:
- 18.08%
- Return on Assets TTM:
- 12.19%
- Return on Equity TTM:
- 21.19%
Company Profile
Dr. Reddy’s Laboratories Limited had its IPO on under the ticker symbol DRREDDY.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Dr. Reddy’s Laboratories Limited has a staff strength of 25,863 employees.
Stock update
Shares of Dr. Reddy’s Laboratories Limited opened at ₹5639.95 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹5626 - ₹5717, and closed at ₹5673.8.
This is a +1.07% increase from the previous day's closing price.
A total volume of 516,202 shares were traded at the close of the day’s session.
In the last one week, shares of Dr. Reddy’s Laboratories Limited have increased by +0.25%.
Dr. Reddy’s Laboratories Limited's Key Ratios
Dr. Reddy’s Laboratories Limited has a market cap of ₹937.09 billion, indicating a price to book ratio of 3.6256 and a price to sales ratio of 3.3632.
In the last 12-months Dr. Reddy’s Laboratories Limited’s revenue was ₹261.11 billion with a gross profit of ₹94.01 billion and an EBITDA of ₹73.82 billion. The EBITDA ratio measures Dr. Reddy’s Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Dr. Reddy’s Laboratories Limited’s operating margin was 23.57% while its return on assets stood at 12.19% with a return of equity of 21.19%.
In Q2, Dr. Reddy’s Laboratories Limited’s quarterly earnings growth was a positive 18% while revenue growth was a positive 29.2%.
Dr. Reddy’s Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 20.5339
- Trailing PE
- 19.8311
- PEG
- 1.5089
Its diluted EPS in the last 12-months stands at ₹283.93 per share while it has a forward price to earnings multiple of 20.5339 and a PEG multiple of 1.5089. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dr. Reddy’s Laboratories Limited’s profitability.
Dr. Reddy’s Laboratories Limited stock is trading at a EV to sales ratio of 3.3101 and a EV to EBITDA ratio of 13.1083. Its price to sales ratio in the trailing 12-months stood at 3.3632.
Dr. Reddy’s Laboratories Limited stock pays annual dividends of ₹40 per share, indicating a yield of 0.72% and a payout ratio of 14.09%.
Balance sheet and cash flow metrics
- Total Assets
- ₹335.04 billion
- Total Liabilities
- ₹80.77 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹12.17 billion
- Dividend Payout Ratio
- 14.09%
Dr. Reddy’s Laboratories Limited ended 2024 with ₹335.04 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹335.04 billion while shareholder equity stood at ₹245.26 billion.
Dr. Reddy’s Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹80.77 billion in other current liabilities, in common stock, ₹230.02 billion in retained earnings and ₹4.24 billion in goodwill. Its cash balance stood at ₹6.02 billion and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹3.80 billion.
Dr. Reddy’s Laboratories Limited’s total current assets stands at ₹210.26 billion while long-term investments were ₹4.90 billion and short-term investments were ₹53.03 billion. Its net receivables were ₹77.10 billion compared to accounts payable of ₹55.36 billion and inventory worth ₹52.40 billion.
In 2024, Dr. Reddy’s Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹12.17 billion.
Comparatively, Dr. Reddy’s Laboratories Limited paid ₹0.14 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹5673.8
- 52-Week High
- ₹5986.2002
- 52-Week Low
- ₹3965.0985
- Analyst Target Price
- ₹
Dr. Reddy’s Laboratories Limited stock is currently trading at ₹5673.8 per share. It touched a 52-week high of ₹5986.2002 and a 52-week low of ₹5986.2002. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹5552.88 and 200-day moving average was ₹4768.19 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 820.1% of the company’s stock are held by insiders while 7070.2% are held by institutions.
Frequently Asked Questions About Dr. Reddy’s Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.